BENEV Company and Hugel Inc. have announced the full commercialization of Letybo (letibotulinumtoxinA-wlbg) in the United States. This product is the sixth neuromodulator to receive FDA approval in the last two decades and is already established as the top-selling neuromodulator in South Korea. The launch is supported by extensive clinical data and over 31 million global treatments, aiming to provide a new competitive option in the U.S. aesthetic market.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.